SV

Street Verdict

Analyst Scorecard

A record of what CA Rudramurthy BV said publicly, with the source. Not advice.

Pending — not yet graded
“Recommends buying Biocon at current market price, targeting an initial level of 400, with a stop loss at 365. This call is based on the strong performance of the pharma sector and Biocon itself.”

CA Rudramurthy BV’s track record (trackable calls only): 33 graded calls · 95% CI 27–59%

BioconBullishCalled 04 Jul 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Biocon since this call

1-year tracking window
Read the original articleSee CA Rudramurthy BV’s full track record